Journal article
Nucleic Acid Aptamers as Novel Class of Therapeutics to Mitigate Alzheimer's Disease Pathology
University of Queensland1
Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark2
Bacterial Cell Factories, Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark3
Deakin University4
Department of Systems Biology, Technical University of Denmark5
Deposition of amyloid-beta (A beta) peptides in the brain is a central event in the pathogenesis of Alzheimer's disease (AD), which makes A beta peptides a crucial target for therapeutic intervention. Significant efforts have been made towards the development of ligands that bind to A beta peptides with a goal of early detection of amyloid aggregation and the neutralization of A toxicity.
Short single-stranded oligonucleotide aptamers bind with high affinity and specificity to their targets. Aptamers that specifically bind to A beta monomers, specifically the 40 and 42 amino acid species (A beta(1-40) and A beta(1-42)), fibrils and plaques have a great potential for diagnostic applications and the treatment of AD.
Herein, we review the aptamers that bind to the various forms of A beta peptides for use in diagnosis and to inhibit plaque formation.
| Language: | English |
|---|---|
| Year: | 2013 |
| Pages: | 442-448 |
| ISSN: | 18755828 and 15672050 |
| Types: | Journal article |
| DOI: | 10.2174/1567205011310040009 |
| ORCIDs: | Lauridsen, Lasse Holm |
